Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

The drug industry is always in full lobbying mode. Photo: Bill Clark / CQ Roll Call via Getty Images

The pharmaceutical industry was busy last week, winning a key exclusion in the budget bill while getting handed a separate loss. And now as the White House releases its budget promoting drug pricing reforms — and as Alex Azar heads to the Hill to discuss them — pharma is still going to find itself on defense.

Why this matters: Pharma is one of the most powerful industries in the country, and generally gets what it wants. But drug prices are an extremely political topic pitting the vast majority of the public against the drug industry, and this week may reveal how that's going to play out in an election year.

What happened last week: Congress included a change to the Medicare Part D "donut hole" in its budget deal, increasing drug companies' share of the bill to close that coverage gap.

  • The budget deal also repealed the Affordable Care Act's Independent Payment Advisory Board. Although hospitals and doctors were the loudest voices advocating for Congress to get rid of it, pharma also wanted it vanquished.
  • "IPAB was probably more terrifying to them than any provider group," said Rodney Whitlock, a former GOP Finance Committee aide who now lobbies for the Campaign for Sustainable Rx Pricing. "They are terrified of bureaucracy having the authority to do things to them that they can't win legislatively."
  • Then on Friday, the Trump administration previewed drug pricing reforms that'll be included in today's budget and released a white paper detailing similar policy suggestions from the Council of Economic Advisors.

What didn't happen last week: The CREATES Act — a measure to give generics easier access to the brand-name drugs they wish to copy — wasn't included in the budget deal, thanks to key Republicans including Sen. Lamar Alexander and Majority Leader Mitch McConnell and, by most accounts, lobbying by the drug industry.

  • "Republicans wouldn’t include it" in the budget deal, a senior Senate Democratic aide said. "Dems made a big push so it was fairly serious."
  • Republicans say they offered an unspecified different solution to the underlying issue — generic companies' ability to obtain samples of brand-name drugs — but Democrats rejected it. The changes would have "gutted the bill," the Democratic aide said.
  • "The underlying issue is a problem that needs to be resolved. But not by giving away the store to trial lawyers," a senior GOP aide said. CREATES would open a pathway to generics to sue brand-name manufacturers to obtain product samples.
  • Some lobbyists said pharma was so busy lobbying against the inclusion of CREATES that they overlooked the donut hole provision's inclusion.

Be smart: Nothing that happened last week includes major structural reform, and drug companies are still reaping gigantic windfalls from tax reform. The administration's proposals are only conceptual, and don't include big policy changes like Medicare price negotiations. Drug companies also can offset the new donut hole policy's impact by simply raising prices.

  • Forcing drug companies to shoulder more of the coverage gap costs will encourage them to jack up list prices so patients quickly enter catastrophic coverage — where taxpayers pick up a vast majority of the costs.
  • "This will impact the decisions about list prices, and it won’t be downward," a drug lobbyist said.
  • The $10 billion in savings the donut hole provision is expected to save taxpayers pales in comparison to the tax breaks drug companies are boasting about. Gilead Sciences expects to repatriate $28 billion this year. AbbVie is forecasting an effective tax rate of just 9% this year, well below the new 21% corporate rate.

The bottom line: "This was not a disastrous week for pharma, no matter how much they want to convince people it was," Whitlock said. "Next week they need to be concerned…because they will have to, once again, engage in the process of convincing people it's not their fault.”

Go deeper

China deems all cryptocurrency transactions illegal

A person walking past China's central bank in Beijing in August 2007. Photo: Teh Eng Koon/AFP via Getty Images

China's central bank declared on Friday that all cryptocurrencies are illegal, banning crypto-related transactions and cryptocurrency mining, according to Reuters.

Why it matters: China's government is now following through with its goal of cracking down on unofficial virtual currencies, which it has said are a financial, social and national security risk and a contributor to global warming.

Biden's big bet backfires

Two key dealmakers — Sen. Joe Manchin (D-W.Va.) and Sen. Mark Warner (D-Va.) — leave a luncheon in the Capitol yesterday. Photo: Kent Nishimura/L.A. Times via Getty Images

President Biden bit off too much, too fast in trying to ram through what would be the largest social expansion in American history, top Democrats privately say.

Why it matters: At the time Biden proposed it, he had his mind set on a transformational accomplishment that would put him in the pantheon of FDR and JFK.

Biden sinks in swing districts

Photo: Biden speaks about wild fires and climate change in Sacramento on September 13, 2021. Photo: Brendan Smialowski/ AFP via Getty Images

Sudden doubts about President Biden's competence — on Afghanistan, immigration and COVID — are driving double-digit drops in his approval in private polling in swing House seats, The Cook Political Report's Amy Walter writes.

Why it matters: "[T]hese early mistakes go directly to the very rationale of his presidency; that it would be low drama and high competence."